Oppenheimer Initiates ProQR Coverage with Outperform and $9 Target – Unmet Need in Liver Diseases Drives Optimism

Oppenheimer starts ProQR Therapeutics (PRQR) coverage with Outperform rating and $9 price target, citing RNA editing potential in liver diseases ahead of 2026 data.